Article info

PDF

CASE REPORT
Long-lasting response to afatinib that persisted after treatment discontinuation in a case of EGFR-mutated lung adenocarcinoma

Authors

  1. Correspondence to Dr Yoshitaka Seki, ms97-seki{at}jikei.ac.jp
View Full Text

Citation

Yamanaka Y, Seki Y, Ishikawa T, et al
Long-lasting response to afatinib that persisted after treatment discontinuation in a case of EGFR-mutated lung adenocarcinoma

Publication history

  • Accepted December 18, 2018
  • First published January 31, 2019.
Online issue publication 
January 31, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.